SIGLEC9: A Potential Drug Target and Biomarker for Neurological Disorders

Target Name: SIGLEC9

NCBI ID: G27180

SIGLEC9

SIGLEC9: A Potential Drug Target and Biomarker for Neurological Disorders

SIGLEC9 (SIGL9_HUMAN) is a protein that is expressed in various tissues of the human body, including the nervous system, endocrine system, and gastrointestinal system. It is a member of the SIGLEC family, which is a family of transmembrane proteins that play a crucial role in intracellular signaling.

SIGLEC9 is known for its role in regulating the levels of various signaling molecules, including neurotransmitters and hormones. It is also involved in the regulation of cellular processes such as cell adhesion, migration, and survival.

One of the unique features of SIGLEC9 is its ability to interact with multiple signaling pathways, including those that involve neurotransmitters, hormones, and cell surface molecules. This makes it an attractive drug target for researchers looking for new treatments for a range of neurological and endocrine disorders.

SIGLEC9 has also been shown to play a role in the development and progression of certain diseases, including neurodegenerative disorders and cancer. For example, studies have shown that SIGLEC9 is expressed in the brains of individuals with Alzheimer's disease, and that it is involved in the regulation of neurotransmitter levels in these individuals.

In addition to its potential as a drug target, SIGLEC9 is also a potential biomarker for certain diseases. For example, research has shown that SIGLEC9 is expressed in the brains of individuals with Parkinson's disease, and that it is involved in the regulation of neurotransmitter levels in these individuals. This suggests that SIGLEC9 could be used as a biomarker for Parkinson's disease, and could potentially be used to identify individuals at risk for this disease.

SIGLEC9 is also a potential target for small molecules, which are drugs that can be used to modulate the activity of SIGLEC9. This is an attractive feature of SIGLEC9 because it allows researchers to use a variety of small molecules to treat a wide range of neurological and endocrine disorders.

In conclusion, SIGLEC9 is a protein that is expressed in various tissues of the human body, and is involved in the regulation of intracellular signaling. Its unique ability to interact with multiple signaling pathways makes it an attractive drug target for researchers looking for new treatments for a range of neurological and endocrine disorders. Furthermore, SIGLEC9 is also a potential biomarker for certain diseases and can be used as a target for small molecules.

Protein Name: Sialic Acid Binding Ig Like Lectin 9

Functions: Putative adhesion molecule that mediates sialic-acid dependent binding to cells. Preferentially binds to alpha-2,3- or alpha-2,6-linked sialic acid. The sialic acid recognition site may be masked by cis interactions with sialic acids on the same cell surface

The "SIGLEC9 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SIGLEC9 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets